InVivo Therapeutics Announces Presentation at the Upcoming H.C Wainwright Virtual Global Investment Conference
September 11 2020 - 8:30AM
Business Wire
InVivo Therapeutics Holdings Corp. (Nasdaq: NVIV), a
research and clinical-stage biomaterials and biotechnology company
with a focus on treatment of spinal cord injuries (SCIs), today
announced that Richard Toselli, M.D., President and Chief Executive
Officer, will present at the upcoming H.C. Wainwright Virtual
Global Investment Conference. The presentation is scheduled for
Wednesday, September 16, 2020 at 11:00 am Eastern Time. A live
webcast will be available at
https://wsw.com/webcast/hcw7/nviv/1631915. Dr. Toselli will discuss
recent company updates, including updates related to the Company’s
ongoing INSPIRE 2.0 Study for acute thoracic SCI. In addition to
the presentation, Dr. Toselli will also be available for one-on-one
meetings with investors who are registered to attend the
conference, which runs from September 14 – 16, 2020.
About InVivo Therapeutics
InVivo Therapeutics (Nasdaq: NVIV) is a clinical-stage
biotechnology company focused on redefining the treatment of spinal
cord injury. InVivo’s proprietary and investigational Neuro-Spinal
Scaffold, based on technology licensed from Robert S. Langer’s lab
at Massachusetts Institute of Technology, is in pivotal clinical
studies for acute spinal cord injury. The company is headquartered
in Cambridge, MA. For more details, visit
www.invivotherapeutics.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200911005057/en/
Investor Contact: Bret Shapiro, Managing Partner CORE IR
brets@coreir.com (516) 222-2560
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Aug 2024 to Sep 2024
InVivo Therapeutics (NASDAQ:NVIV)
Historical Stock Chart
From Sep 2023 to Sep 2024